CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the third quarter of 2011 and provided an update on its corporate developments.
“At the same time, AP26113, our unique, investigational dual-inhibitor of ALK and EGFR, has advanced into the clinic, and we believe that it may address a major unmet medical need in two clinically important, molecularly defined subgroups of patients with non-small cell lung cancer.” “The clinical development and potential commercialization of ponatinib, our investigational pan-BCR-ABL inhibitor, are moving ahead as planned, and we look forward to the presentation of interim data on ponatinib from the pivotal PACE trial next month,” stated Harvey J. Berger, M.D., chairman and chief executive officer.
“At the same time, AP26113, our unique, investigational dual-inhibitor of ALK and EGFR, has advanced into the clinic, and we believe that it may address a major unmet medical need in two clinically important, molecularly defined subgroups of patients with non-small cell lung cancer.” “The clinical development and potential commercialization of ponatinib, our investigational pan-BCR-ABL inhibitor, are moving ahead as planned, and we look forward to the presentation of interim data on ponatinib from the pivotal PACE trial next month,” stated Harvey J. Berger, M.D., chairman and chief executive officer.
